US 12,138,304 B2
HIV-1 envelope stabilizing mutations
Rory Henderson, Durham, NC (US); S. Munir Alam, Durham, NC (US); Barton F. Haynes, Durham, NC (US); and Kevin J. Wiehe, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Appl. No. 17/281,918
Filed by Duke University, Durham, NC (US)
PCT Filed Sep. 5, 2019, PCT No. PCT/US2019/049662
§ 371(c)(1), (2) Date Mar. 31, 2021,
PCT Pub. No. WO2020/072169, PCT Pub. Date Apr. 9, 2020.
Claims priority of provisional application 62/739,727, filed on Oct. 1, 2018.
Prior Publication US 2021/0379177 A1, Dec. 9, 2021
Int. Cl. A61K 39/12 (2006.01); C07K 14/16 (2006.01); C12N 7/00 (2006.01); C12N 15/63 (2006.01)
CPC A61K 39/12 (2013.01) [C07K 14/162 (2013.01); C12N 7/00 (2013.01); C12N 15/63 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01)] 12 Claims
 
1. A modified recombinant HIV-1 envelope comprising a valine to isoleucine mutation at amino acid position 68, an alanine to valine mutation at amino acid position 204, a valine to leucine mutation at amino acid position 208, and a valine to leucine mutation at amino acid position 255, wherein the amino acid positions refer to HXB2 numbering in an unmodified HIV-1 envelope.